Skip to main content
. 2019 Feb 24;10(2):38–51. doi: 10.5306/wjco.v10.i2.38

Table 2.

Summary of selected publications reporting stereotactic body radiation therapy for lymph nodes oligometastatic prostate cancer

Ref. Study type No. Patients / lesions No. of metastases Imaging method Site of metastases SBRT schedules LC PFS
Lymph node
Casamassima et al[33] R 25/25 NR Cholina PET/CT LN N = 18: 30 Gy/3 fr 90% (3 yr) Median 24 mo
Detti et al[36] R 30/39 NR Cholina PET/CT LN 24-36 Gy/1-5 fr 100% (1 yr) NR
Ponti et al[60] R 16/18 ≤ 2 Cholina PET/CT LN 12-35 Gy/1-5 fr 94% (2 yr) NR
Ost et al[29] R 72/89 ≤ 3 18F-FDG, Cholina PET/CT,MRI LN At least 5 Gy/fr with BED at least 80 Gy 95.8% (3 yr) Median 21 mo 34% (3 yr) 13% (5 yr)
Ingrosso et al[61] R 40/47 NR Cholina PET/CT LN 35-40 Gy/5 fr (+ frequent) 98% (mean FU 30 mo) NR
Jereczek-Fossa et al[62] R 94/124 ≤ 5 Cholina PET/CT/CT/MRI LN 24-30 Gy/3 fr (+ frequent) 84% (2 yr) 30% (2 yr)

BED: Biologically effective dose; CT: Computed tomography; 18F-FDG: [18F]-fluorodeoxyglucose; LC: Local control; LN: Lymph node; MRI: Magnetic resonance imaging; NR: Not reported; PET/CT: Positron emission tomography with coregistered computed tomography; PFS: Progression free survival; R: Retrospective; SBRT: Stereotactic body radiation therapy.

HHS Vulnerability Disclosure